Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Keith Goldan Sells 3,410 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith Goldan sold 3,410 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the completion of the transaction, the chief financial officer directly owned 140,429 shares of the company’s stock, valued at $2,953,221.87. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $21.32 on Wednesday. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. The company’s fifty day simple moving average is $20.77 and its 200 day simple moving average is $17.23. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $22.73. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -5.91 and a beta of 0.46.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently made changes to their positions in SNDX. Bank of New York Mellon Corp increased its stake in shares of Syndax Pharmaceuticals by 4.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,094,151 shares of the company’s stock worth $22,988,000 after purchasing an additional 41,816 shares during the period. Goldman Sachs Group Inc. grew its holdings in Syndax Pharmaceuticals by 3.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,695,375 shares of the company’s stock valued at $119,660,000 after buying an additional 208,941 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of Syndax Pharmaceuticals by 20.4% during the fourth quarter. Intech Investment Management LLC now owns 40,793 shares of the company’s stock worth $857,000 after buying an additional 6,918 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in shares of Syndax Pharmaceuticals by 91.9% during the fourth quarter. Simplify Asset Management Inc. now owns 54,715 shares of the company’s stock worth $1,150,000 after buying an additional 26,210 shares in the last quarter. Finally, PSP Research LLC bought a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at about $519,000.

Wall Street Analyst Weigh In

A number of research firms recently commented on SNDX. Barclays lifted their price target on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research report on Monday, December 29th. UBS Group lifted their target price on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Syndax Pharmaceuticals in a report on Monday, October 27th. Finally, BTIG Research reaffirmed a “buy” rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.